See more : KESAR INDIA LIMITED (KESAR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Medexus Pharmaceuticals Inc. (MEDXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medexus Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- RocketBoots Limited (ROC.AX) Income Statement Analysis – Financial Results
- One Point One Solutions Limited (ONEPOINT.NS) Income Statement Analysis – Financial Results
- The Takigami Steel Construction Co., Ltd. (5918.T) Income Statement Analysis – Financial Results
- H.U. Group Holdings, Inc. (MRCHF) Income Statement Analysis – Financial Results
- Proteome Sciences plc (PRM.L) Income Statement Analysis – Financial Results
Medexus Pharmaceuticals Inc. (MEDXF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.medexus.com
About Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 113.05M | 108.10M | 76.70M | 79.66M | 52.43M | 25.36M | 7.75M | 4.65M | 2.89M | 3.69M | 3.07M | 0.00 | 0.00 |
Cost of Revenue | 53.54M | 48.06M | 38.77M | 37.66M | 22.99M | 10.38M | 3.85M | 2.08M | 998.43K | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 59.51M | 60.04M | 37.93M | 42.01M | 29.44M | 14.98M | 3.90M | 2.57M | 1.89M | 3.69M | 3.07M | 0.00 | 0.00 |
Gross Profit Ratio | 52.64% | 55.54% | 49.45% | 52.73% | 56.15% | 59.08% | 50.37% | 55.24% | 65.44% | 100.00% | 100.00% | 0.00% | 0.00% |
Research & Development | 8.04M | 2.94M | 5.87M | 4.60M | 1.10M | 0.00 | 0.00 | 0.00 | 0.00 | 542.62K | 1.38M | 0.00 | 0.00 |
General & Administrative | 27.86M | 36.86M | 34.52M | 19.28M | 11.77M | 5.64M | 1.58M | 2.15M | 2.72M | 1.21M | 2.02M | 149.56K | 136.14 |
Selling & Marketing | 10.58M | 11.39M | 9.51M | 16.89M | 17.16M | 9.97M | 4.51M | 2.95M | 2.48M | 3.15M | 4.70M | 0.00 | 0.00 |
SG&A | 38.44M | 48.25M | 44.03M | 36.17M | 28.93M | 15.62M | 6.09M | 5.10M | 5.20M | 4.36M | 6.72M | 149.56K | 136.14 |
Other Expenses | 2.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 48.72M | 51.55M | 50.30M | 41.27M | 30.48M | 15.66M | 6.10M | 5.12M | 5.28M | 4.90M | 8.10M | 149.56K | 136.14 |
Cost & Expenses | 102.26M | 99.61M | 89.08M | 78.93M | 53.47M | 26.04M | 9.95M | 7.20M | 6.28M | 4.90M | 8.10M | 149.56K | 136.14 |
Interest Income | 0.00 | 0.00 | 0.00 | 3.00K | 205.89K | 161.72K | 30.82K | 29.96K | 31.95K | 23.21K | 49.23K | 0.00 | 0.00 |
Interest Expense | 13.36M | 13.61M | 12.22M | 9.82M | 6.44M | 2.90M | 918.90K | 501.78K | 732.52K | 269.44K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 5.81M | 8.05M | 7.71M | 7.90M | 5.26M | 2.38M | 231.16K | 51.87K | 113.48K | 88.12K | 0.00 | 0.00 | 0.00 |
EBITDA | 19.28M | 14.65M | 15.16M | -23.61M | 7.04M | 159.00K | -2.06M | -697.72K | -1.15M | -3.85M | -4.88M | -2.02M | -136.14 |
EBITDA Ratio | 17.05% | 13.48% | -8.12% | 8.43% | 3.25% | 5.58% | -25.62% | -59.93% | -113.69% | -31.76% | -159.09% | 0.00% | 0.00% |
Operating Income | 10.79M | 7.61M | -15.00M | -1.38M | -5.41M | -4.39M | -2.18M | -592.05K | -1.03M | -1.21M | -4.88M | -149.56K | -136.14 |
Operating Income Ratio | 9.55% | 7.04% | -19.55% | -1.73% | -10.32% | -17.32% | -28.09% | -12.72% | -35.72% | -32.78% | -159.09% | 0.00% | 0.00% |
Total Other Income/Expenses | -10.69M | -12.66M | 11.18M | -30.13M | 244.00K | -477.99K | -501.00K | -584.12K | -431.64K | 38.83K | -117.08K | 0.00 | 0.00 |
Income Before Tax | 106.00K | -5.04M | -3.82M | -31.50M | -5.19M | -4.72M | -2.70M | -1.37M | -1.77M | -3.22M | -5.00M | -149.56K | -136.14 |
Income Before Tax Ratio | 0.09% | -4.66% | -4.98% | -39.54% | -9.89% | -18.60% | -34.79% | -29.51% | -61.31% | -87.14% | -162.90% | 0.00% | 0.00% |
Income Tax Expense | 320.00K | -6.26M | -941.00K | -3.24M | -790.44K | 166.29K | 918.90K | 501.78K | 732.52K | 269.44K | 0.00 | 0.00 | 0.00 |
Net Income | -214.00K | 1.22M | -2.88M | -28.26M | -4.40M | -4.88M | -2.70M | -1.37M | -1.77M | -3.22M | -5.00M | -149.56K | -136.14 |
Net Income Ratio | -0.19% | 1.13% | -3.75% | -35.48% | -8.39% | -19.26% | -34.79% | -29.51% | -61.31% | -87.14% | -162.90% | 0.00% | 0.00% |
EPS | -0.01 | 0.06 | -0.15 | -1.86 | -0.31 | -0.49 | -0.47 | -0.28 | -0.37 | -0.67 | -0.07 | -0.27 | 0.00 |
EPS Diluted | -0.01 | 0.06 | -0.14 | -1.86 | -0.31 | -0.49 | -0.47 | -0.28 | -0.37 | -0.67 | -0.07 | -0.27 | 0.00 |
Weighted Avg Shares Out | 22.32M | 19.98M | 19.45M | 15.20M | 14.36M | 9.91M | 5.68M | 4.84M | 4.83M | 4.80M | 72.06M | 544.00K | 177.78K |
Weighted Avg Shares Out (Dil) | 22.32M | 20.52M | 19.86M | 15.20M | 14.36M | 9.91M | 5.68M | 4.84M | 4.83M | 4.80M | 72.06M | 544.00K | 177.78K |
Medexus Schedules Webinar to Discuss FDA Complete Response Letter for Treosulfan
Complete Response Letter Received from FDA for Treosulfan
Medexus Appoints New Chief Financial Officer
Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada
Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada
Medexus Pharmaceuticals Inc. (MEDXF) CEO Ken d'Entremont on Q4 2021 Results - Earnings Call Transcript
Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021
Medexus Announces Graduation to the Toronto Stock Exchange
Medexus to Present at Raymond James Human Health Innovation Conference
Medexus Schedules Fiscal Year 2021 Conference Call
Source: https://incomestatements.info
Category: Stock Reports